78502-71-3

Usage

Uses

Used in Organic Synthesis:
ETHYL 2-(BROMOMETHYL)-1,3-THIAZOLE-4-CARBOXYLATE is used as a reagent for the preparation of thiazole derivatives, which are valuable in the development of pharmaceutical compounds due to their diverse biological activities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, ETHYL 2-(BROMOMETHYL)-1,3-THIAZOLE-4-CARBOXYLATE serves as an intermediate in the synthesis of various drugs. Its unique structure contributes to the creation of new therapeutic agents with potential applications in treating different diseases.
Used in Antimicrobial Applications:
ETHYL 2-(BROMOMETHYL)-1,3-THIAZOLE-4-CARBOXYLATE has been studied for its potential antimicrobial properties, making it a candidate for use in applications where resistance to common antibiotics is a concern.
Used in Pesticidal Applications:
ETHYL 2-(BROMOMETHYL)-1,3-THIAZOLE-4-CARBOXYLATE has also been investigated for its pesticidal properties, suggesting that it could be utilized in the development of new pesticides for agricultural and environmental purposes.
Used in Research and Development:
Due to its potential applications, ETHYL 2-(BROMOMETHYL)-1,3-THIAZOLE-4-CARBOXYLATE is used in research and development settings to explore its full range of capabilities and to innovate new uses in various industries.
It is crucial to handle ETHYL 2-(BROMOMETHYL)-1,3-THIAZOLE-4-CARBOXYLATE with care, as it is a potentially hazardous chemical that should be used in a controlled laboratory environment to ensure safety and proper containment.

Upstream product

• 6436-59-5 ethyl 2-methylthiazole-4-carboxylate 
• 94-36-0 dibenzoyl peroxide 

Downstream Products

• 1204771-06-1 2-{(3-phenyl-1H-indazol-1-yl)methyl}thiazole-4-carboxylic acid 
• 1204771-07-2 ethyl 2-((3-phenyl-6-(trifluoromethyl)-1H-indazol-1-yl)methyl)thiazole-4-carboxylate 
• 1351369-84-0 C₂₅H₂₈N₂O₃S 
• 1282549-56-7 ethyl 2-{[(tert-butoxycarbonyl)(3-phenylpropyl)aminomethyl]methyl}-1,3-thiazole-4-carboxylate 
• 1282544-10-8 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-N-(phenylsulfonyl)-1,3-thiazole-4-carboxamide 
• 1282544-36-8 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-N-{[(2-hydroxyethyl)amino]sulfonyl}-1,3-thiazole-4-carboxamide 
• 1282544-33-5 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-N-[(3-oxopyrrolidin-1-yl)sulfonyl]-1,3-thiazole-4-carboxamide 
• 1282544-16-4 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-N-[(3-hydroxypyrrolidin-1-yl)sulfonyl]-1,3-thiazole-4-carboxamide 
• 1282549-96-5 N-[(3-{[tert-butyl (dimethyl)silyl]oxy}pyrrolidin-1-yl)sulfonyl]-2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-1,3-thiazole-4-carboxamide 
• 1282549-22-7 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-1,3-thiazole-4-carboxylic acid 
• 1282549-79-4 ethyl 2-{[(3,5-dimethoxy-4-methylbenzoyl)(3-phenylpropyl)amino]methyl}-1,3-thiazole-4-carboxylate 
• 1282549-53-4 ethyl 2-{[(3-phenylpropyl)amino]methyl}-1,3-thiazole-4-carboxylate 
• 1263298-23-2 Ethyl 2-(6-fluoro-5-methoxy-2-phenylindol-1-ylmethyl)thiazole-4-carboxylate 
• 1256240-34-2 2-hydroxymethylthiazole-4-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Design, synthesis, and antitumor activity evaluation of pretubulysin analogs

Pretubulysin, a biosynthetic precursor of the tubulysins, shows potent biological activity in a variety of tumor cell lines. Although there are several total synthesis routes to tubulysin and pretubulysin reported, the commercialization still has been hampered due to the complexity of the structure. To find structurally simpler pretubulysin analogs, a series of 2-(3-(methylamino)propyl)thiazole-4-carboxamides are designed and synthesized, and their anticancer activities are screened using MCF-7 (breast cancer), and NCI-H157 (lung cancer) cell lines. Taxol (IC50?=?0.01?μM) and pretubulysin are used as the control. Compounds 8c (IC50?=?0.05?μM, MCF-7; 0.09?μM, NCI-H157) and 8h (IC50?=?0.01?μM, MCF-7; 0.02?μM, NCI-H157) exhibited certain antitumor activities comparable to those of Taxol. The urea analogs of pretubulysin might represent a promising scaffold for the further development of novel antitumor drugs.

ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE

The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.

Sulfur-containing compound based on glutaryl imide skeleton and application of compound

The present disclosure relates to compound shown in a formula (I) or salts, solvates, isotope-enriched analogs, tautomers, polymorphs, stereoisomers, or mixtures of stereoisomers of the compound, andthe application thereof in the treatment of tumours. The present disclosure also provides tumor treatment application of the compound showed in a formula (I') or pharmaceutically acceptable salts, solvates, isotope-enriched analogs, tautomers, polymorphic substances, stereoisomers, or mixtures of stereoisomers of the compound.

SUBSTITUTED AMIDE COMPOUND

A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or —(CRX1RX2)n—; n is 1, 2, 3, or 4; RX1 and RX2 are hydrogen, etc.; Y1 to Y5 are each CRY or N; each RY is hydrogen, etc.; R1 and R2 are hydrogen, etc.; m is 1, 2, or 3; R3 is hydrogen, etc.; and R4 is an optionally substituted lower alkyl, etc.

NEW BRADYKININ B1 ANTAGONISTS

The invention relates to compounds of formula (I) where in R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds as well as the production and use as medicament.

Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues

New compounds derived from inhibitors of histone deacetylases (HDACs) have been synthesized and their antiproliferative activities towards non small lung cancer cell line H661 evaluated. Their design is based on hybrids between indanones to limit conformational mobility and other known HDAC inhibitors (SAHA, MS-275). The synthesis of these new derivatives was achieved by alkylation of appropriate indanones to introduce the side chain bearing a terminal ester group, the latter being a precursor of hydroxamic acid and aminobenzamide derivatives. These new analogues were found to be moderately active to inhibit H661 cell proliferation.

Biaryloxymethylarenecarboxylic acids as glycogen synthase activators

The present invention relates to compounds of formula (I) wherein Ar, Ar2, R2, R3, R4, m, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases that are associated with the activation of the glycogen synthase enzyme, such as diabetes.

HYDRAZONE DERIVATIVE

A compound represented by the following formula (I): wherein R1 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R2 represents hydrogen, aryl which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc.; R3 represents hydrogen, etc.; Ar represents a divalent group derived from aromatic hydrocarbon, etc.; X represents a single bond, linear or branched alkylene having from 1 to 3 carbon atoms which may have a substituent, etc.; and G represents halogen, a saturated or unsaturated 5- or 6-membered cyclic hydrocarbon group which may have a substituent, a saturated or unsaturated 5- to 7-membered heterocyclic group which may have a substituent, etc., a salt thereof or a solvate thereof; and an agent for inhibiting aggregation and/or deposition of an amyloid protein or an amyloid-like protein, which comprises the compound, a salt thereof or a solvate thereof

Biaryloxymethylarenecarboxylic acids as glycogen synthase activator

The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, m, n, p and s are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases that are associated with the activation of the glycogen synthase enzyme, such as diabetes.

Arylpiperazine substituted heterocycles as selective alpha(1a) adrenergic antagonists.

Antagonists of the alpha(1)-adrenergic receptors (alpha(1)-ARs) are useful for the treatment of benign prostatic hyperplasia. A series of potent and subtype-selective alpha(1a)-AR antagonists has been synthesized, displaying in vitro binding affinity in the low the nanomolar range.